Epithalon 50mg Peptide

Epithalon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, four residues and 390.35 g/mol. It was designed in the 1990s at the St Petersburg Institute of Bioregulation and Gerontology by the group of Vladimir Khavinson, working backwards from the amino acid composition of Epithalamin, a crude polypeptide extract of bovine pineal gland that the same institute had been studying since the 1970s. The idea was that the extract's activity might reside in one short sequence, and that a defined tetrapeptide would be easier to characterise than a mixture.

That premise went unconfirmed for two decades. In 2017 the group ran mass spectrometry and HPLC on the pineal polypeptide complex and reported its composition as 3.26% free amino acids, 23.19% dipeptides, 50.72% tripeptides, 22.10% tetrapeptides and 0.72% pentapeptides, with AEDG detected among the tetrapeptides by selective reaction monitoring. The peptide sold as Epithalon is therefore a synthetic copy of a sequence now reported to occur in the gland, not a designed molecule with no natural counterpart.

Epitalon, Epithalon and Epithalone are the same compound under three transliterations of the same Russian name, and AEDG peptide is the sequence written as single letters. Epithalamin is not a fourth spelling of the same thing: it is the bovine extract, and a large part of the human data circulating under the tetrapeptide's name actually belongs to it. As of August 2026 a search of ClinicalTrials.gov for epitalon, epithalon, AEDG and epithalamin returns no registered studies.

The finding the compound is known for came from a 2003 experiment in telomerase-negative human fetal fibroblast culture. Adding Epithalon induced expression of the telomerase catalytic subunit, produced measurable telomerase enzymatic activity, and elongated telomeres in cells that had none of that activity to begin with. Treated cultures kept dividing past the 44th passage while controls stopped at the 34th. The interpretation offered was reactivation of a telomerase gene that somatic cells normally keep silent.

That result went twenty-two years without an independent quantitative replication. In 2025 a group at Brunel University London treated two breast cancer lines, 21NT and BT474, alongside normal epithelial cells and fibroblasts, then measured telomere length by qPCR and telomerase protein by immunofluorescence. In the normal cells telomeres lengthened dose-dependently through hTERT mRNA and telomerase upregulation, matching the 2003 claim. In the cancer lines telomeres also lengthened, but through Alternative Lengthening of Telomeres, a recombination-based pathway that does not need telomerase; ALT activity rose only slightly in the normal cells. A correction to that paper was published in Biogerontology in November 2025.

No receptor has been identified. The proposed route is direct contact with DNA and chromatin. A complementary binding model published in 2005 assigned AEDG to an ATTTTC base-pair block found repeatedly in the promoter region of telomerase, and 2013 molecular mechanics work modelled AEDG at ATTTC sites in the promoters of CD5, IL-2, MMP2 and Tram1. Separate molecular modelling placed AEDG on histone H1/3 and H1/6 at the His-Pro-Ser-Tyr-Met-Ala-His-Pro-Ala-Arg-Lys and Tyr-Arg-Lys-Thr-Gln sites that contact DNA. In vitro, the presence of Epitalon lowered the melting temperature of double-stranded DNA by as much as 41 degrees Celsius, which is the physical observation the strand-separation model rests on. These are computational and biophysical arguments, not a solved co-crystal structure.

The pineal and melatonin mechanism is asserted far more often than it is demonstrated. Khavinson's group reports that AEDG raised urinary 6-sulfatoxymelatonin excretion 1.7-fold in middle-aged people whose baseline output was low, normalised elevated Clock and Csnk1e expression in leukocytes by 1.9 to 2.1-fold, and doubled depressed Cry2 expression in blood lymphocytes. Against that, an independent Paris group perifused pineal glands from young 9-week-old and old 27-month-old male Wistar rats with the tetrapeptide at 10^-4 to 10^-6 M and found no effect on basal melatonin secretion at either age, and no change to the melatonin rise produced by the beta-adrenergic agonist isoproterenol. The gland-level mechanism is unresolved.

A separate and better-replicated line of activity is antioxidant. At 0.1 mM in mouse oocyte culture, Epitalon lowered intracellular reactive oxygen species, raised mitochondrial membrane potential and mitochondrial DNA copy number, and reduced apoptosis by 24 hours of in vitro aging. In high-glucose-injured human retinal pigment epithelial cells the same peptide restored delayed wound closure and suppressed the epithelial-mesenchymal transition and fibrosis gene program the hyperglycaemic insult had switched on.

Epithalamin is a crude polypeptide extract of bovine pineal gland. Epithalon is one defined tetrapeptide, Ala-Glu-Asp-Gly, synthesised to reproduce what the extract did. Databases blur the two: PubChem CID 219042 lists Epithalamin and Epithalamine among the synonyms for the tetrapeptide and carries CAS 64082-79-7 alongside the tetrapeptide's own 307297-39-8. Product pages inherit that blur and then inherit the extract's human data with it.

The specific study that keeps getting attached to the wrong molecule is Korkushko's 12-year randomised follow-up in elderly patients with coronary disease and accelerated cardiovascular aging. Deaths in the treated group were 28% lower than in controls on the same background therapy, cardiovascular mortality was about half, and functional age and exercise tolerance improved. That trial used epithalamine, the pineal peptide preparation, not the tetrapeptide. Because the extract is a mixture of dipeptides through pentapeptides whose composition varies between preparations, no part of that mortality result can be assigned to AEDG specifically.

The two are not interchangeable in potency either. Comparative antioxidant testing summarised in the 2025 Int J Mol Sci review reported the tetrapeptide out-performing the extract even though the extract was given at 1000-fold higher amounts, which is what you would expect if AEDG is one active component diluted in a great deal of inactive material.

Read carefully, the 2003 Bulletin of Experimental Biology and Medicine paper is a single-figure report in one cell type: telomerase-negative human fetal fibroblasts. It is the origin of every telomerase claim made about this compound, and for two decades it stood alone. The 2025 Brunel study is the first published attempt to put quantitative numbers on hTERT mRNA, telomerase enzyme activity, telomere length and ALT activation across several cell types at once.

Its most consequential result is the one that rarely gets repeated. The widely circulated claim is that Epithalon activates telomerase only in normal cells and leaves cancer cells untouched. What the 2025 data show is that telomeres lengthened in the 21NT and BT474 breast cancer lines too. The route was different: normal cells used hTERT and telomerase, the cancer lines used Alternative Lengthening of Telomeres, and ALT activity rose only marginally in the normal cells. Telomere extension being cancer-cell-selective in mechanism is not the same as being absent in cancer cells, and the selectivity argument that sits on most product pages depends on the second claim rather than the first.

The scale of the reported active concentrations is its own oddity. Mitogenic activity on murine thymocytes peaks at 10^-17 to 10^-15 M, and the Drosophila lifespan effect appeared at 0.001 x 10^-6 to 5 x 10^-6 weight percent of culture medium with no dose-response relationship inside that window. Effects that do not scale with concentration across eleven orders of magnitude are difficult to reconcile with a simple binding model, and the 2025 review notes that the precise mechanism remains unverified.

The figure quoted everywhere is 13.3%. It comes from Anisimov's 2003 study in female Swiss-derived SHR mice, 54 animals per group, treated from 3 months of age until natural death with 1 microgram per mouse on five consecutive days each month. What that 13.3% describes is the lifespan of the last 10% of survivors, not the population. Mean lifespan was explicitly unaffected, as were food consumption and body weight. Maximum lifespan rose 12.3%. The same study found no change in total spontaneous tumour incidence, with a 6-fold reduction confined to leukaemia.

The Drosophila result is a different kind of finding again. Wild-strain Canton-S flies exposed only during development, from egg to larva, lived 11 to 16% longer as adults, and the effect was independent of the amount added. The authors noted that the effective concentrations were 16,000 to 80,000,000 times lower than those needed for melatonin in the same assay.

Taken together the rodent and insect data support a geroprotective effect on the tail of the survival curve at exposures measured in micrograms per kilogram. They do not support the claim that the compound raises average lifespan, and the amounts used in the published rodent work are orders of magnitude below the milligram quantities the standard vial sizes imply.

Nearly every description of Epithalon says it restores pineal melatonin production. The direct test of that at the level of the gland is a 2003 study from the Pitie-Salpetriere faculty in Paris, published in the Journal of Endocrinological Investigation, in which pineal glands from young 9-week-old and old 27-month-old male Wistar rats were perifused with the tetrapeptide at 10^-4 to 10^-6 M. Melatonin secretion did not change at either age, and the peptide did not modify the melatonin rise produced by isoproterenol. Khavinson was a co-author.

The supporting evidence points the other way but sits one level removed from the gland. Human work reported by the St Petersburg group, published in Russian in Advances in Gerontology, found urinary 6-sulfatoxymelatonin excretion 1.7-fold higher in middle-aged subjects with reduced baseline output, Clock and Csnk1e overexpression in leukocytes normalised 1.9 to 2.1-fold, and Cry2 underexpression in blood lymphocytes doubled. Those are downstream and circadian-gene readouts rather than pinealocyte secretion, and the reports are single-group, Russian-language and not independently replicated.

The honest reading is that AEDG appears to influence circadian gene expression in humans with disrupted rhythms, and that it does not stimulate melatonin release from isolated rat pineal tissue. Anyone designing an experiment around the melatonin hypothesis should treat the pinealocyte step as open rather than established.

AEDG is supplied as a white lyophilised powder and is unusually hydrophilic even for a short peptide: XLogP -5.5, topological polar surface area 225 square angstroms, seven hydrogen bond donors and ten acceptors. It dissolves readily in water and carries a net negative charge at physiological pH from the glutamate and aspartate side chains plus the free C-terminal carboxyl. Molecular dynamics simulations show two intramolecular salt bridges between the N-terminal alanine amine and those carboxylates, which sharply restrict the peptide's conformational freedom in solution.

Both termini are unprotected. A free N-terminal amine is an aminopeptidase substrate and a free C-terminal acid is a carboxypeptidase substrate, which is the entire chemical rationale behind the acetylated and amidated analogue sold separately. No published head-to-head stability or exposure comparison between AEDG and its blocked analogue exists, so the advantage remains an argument from peptide chemistry rather than a measured one.

Identity and purity are established by reversed-phase HPLC for purity and by mass spectrometry for identity, and LC-MS/MS has been validated specifically for detecting Epitalon in commercial material. The monoisotopic mass of 390.1387 Da is the number a mass spectrum should return. Purity figures on a certificate of analysis describe the lot that was tested and say nothing about sequence correctness on their own, which is why the mass spectrum matters more than the HPLC percentage for a tetrapeptide this short.

Epithalon belongs to a family of very short acidic peptides from the same institute, several of which share its first three residues. Cardiogen is Ala-Glu-Asp-Arg, differing from AEDG only at the fourth position. Vesugen is Lys-Glu-Asp and Pinealon is Glu-Asp-Arg. The family's organising claim is that the fourth residue, or the absence of one, directs which tissue's gene promoters the peptide reaches. That claim rests on the same modelling and microarray methods as the AEDG work and carries the same evidentiary limits, so treating one member's data as support for another is not warranted.

Thymalin sits on the other side of the same divide as Epithalamin: it is a thymic extract, not a defined sequence. The distinction matters when comparing literature, because an extract's effects cannot be attributed to any single peptide within it.

Against the other longevity compounds in this catalogue, Epithalon is mechanistically unlike all of them. MOTS-c and Humanin are mitochondrial-derived peptides signalling through AMPK and gp130 respectively. SS-31 concentrates in the inner mitochondrial membrane by binding cardiolipin. FOXO4-DRI is a senolytic that displaces p53 from FOXO4 to push senescent cells into apoptosis. Epithalon is the only one whose primary reported readout is telomere length itself, and the only one whose proposed mechanism is direct interaction with DNA rather than with a protein target.

There is no published pharmacokinetic study of AEDG in any species. No plasma half-life, no volume of distribution, no clearance, no bioavailability figure by any route has been measured and reported. The 2025 Int J Mol Sci review states plainly that information on this peptide's pharmacokinetics and safety is missing, and that physico-chemical and structural investigation of it remains limited. Any specific half-life number attached to this compound is an estimate presented without a source.

There are also no registered clinical trials. A search of ClinicalTrials.gov in August 2026 for epitalon, epithalon, AEDG and epithalamin returns nothing. The human reports that exist are small, largely Russian-language, and come predominantly from one institute and its collaborators, which means the usual safeguards of independent replication and cross-group peer review have not been applied to most of them.

The open questions worth naming are specific. Whether AEDG raises telomerase activity in a whole organism rather than in culture has not been tested. Whether its ALT activation in cancer lines has any consequence in vivo is unexamined. And whether the circadian gene changes reported in humans reflect a pineal effect or something downstream is exactly what the negative perifusion result leaves unresolved.